AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Levels and durability of humoral and T-specific responses after the booster dose of mRNA BNT162b2 vaccine in residents of a Long Term Care FacilityView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodiesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022SARS-CoV-2 mutations and variants may muddle the sensitivity of COVID-19 diagnostic assaysView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencingView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 wavesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022HIV transmission clusters in Europe: A perspective view of Late presenters and Non-Late presentersView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022HIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub- Saharan Africa: A Systematic Review and Meta-AnalysisView Abstract
AbstractTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021Concentration-QTcF modelling and drug-drug interaction of Bedaquiline, Pretomanid and Clofazimine in TB patients.View Abstract
AbstractTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021Incidence and determinants of linezolid toxicity in patients with drug-resistant tuberculosis in a high HIV prevalence settingView Abstract
AbstractTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021Simulation by oral dosing of rifapentine-rifabutin exposures for long-acting formulations in a mouse model of tuberculosis preventive therapyView Abstract
AbstractTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021Rifampin Urine Colorimetry for Evaluation of Tuberculosis PharmacokineticsView Abstract
AbstractTuberculosisInternational Workshop on Clinical Pharmacology of Tuberculosis Drugs 2021Pravastatin pharmacokinetics when administered simultaneously with first-line tuberculosis treatmentView Abstract
